Unichem Laboratories Ltd

₹ 363 -2.54%

05 Jun - close price

unichemlabs.com BSE: 506690 NSE: UNICHEMLAB

About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.^[1]

Key Points

Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. ^[1]

Website BSE NSE

Market Cap ₹ 2,556 Cr.
Current Price ₹ 363
High / Low ₹ 667 / 278
Stock P/E 32.6
Book Value ₹ 386
Dividend Yield 0.00 %
ROCE 3.99 %
ROE 3.03 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Stock is trading at 0.94 times its book value
Company has delivered good profit growth of 23.9% CAGR over last 5 years

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 2.30% over last 3 years.
Contingent liabilities of Rs.980 Cr.
Earnings include an other income of Rs.265 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	402	423	416	466	432	483	507	533	587	527	579	521	575
	386	395	407	435	406	443	452	448	503	504	513	476	527
Operating Profit	16	28	9	31	25	40	55	86	84	22	66	45	48
OPM %	4%	7%	2%	7%	6%	8%	11%	16%	14%	4%	11%	9%	8%
	-28	9	6	79	-119	4	9	14	9	7	-37	287	11
Interest	6	6	7	6	5	4	5	7	5	7	8	7	9
Depreciation	30	29	29	32	27	32	32	31	30	32	31	31	31
Profit before tax	-47	2	-22	73	-126	8	27	62	58	-9	-11	293	19
Tax %	-6%	132%	12%	-0%	3%	74%	9%	6%	8%	16%	10%	10%	42%
	-44	-1	-24	73	-129	2	25	58	53	-10	-12	264	11
EPS in Rs	-6.29	-0.10	-3.48	10.40	-18.37	0.29	3.50	8.22	7.52	-1.49	-1.69	37.54	1.55
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,202	1,333	698	815	1,180	1,104	1,235	1,270	1,343	1,785	2,111	2,202
	1,100	1,169	738	942	1,254	1,153	1,144	1,198	1,389	1,698	1,846	2,018
Operating Profit	101	164	-41	-128	-74	-49	91	72	-46	87	265	184
OPM %	8%	12%	-6%	-16%	-6%	-4%	7%	6%	-3%	5%	13%	8%
	20	15	184	2,735	91	91	50	47	-0	-26	35	265
Interest	3	3	3	8	8	8	5	6	17	23	21	32
Depreciation	41	39	44	51	67	82	84	91	113	123	125	125
Profit before tax	77	137	97	2,548	-58	-48	51	22	-176	-85	155	292
Tax %	3%	21%	-12%	0%	-59%	25%	33%	-50%	15%	10%	11%	14%
	75	108	109	2,545	-24	-60	34	33	-202	-94	138	253
EPS in Rs	8.31	11.90	11.96	361.82	-3.38	-8.55	4.87	4.70	-28.72	-13.32	19.53	35.91
Dividend Payout %	24%	17%	25%	1%	-118%	-47%	82%	85%	-14%	0%	0%	0%

Compounded Sales Growth
10 Years:	5%
5 Years:	12%
3 Years:	18%
TTM:	4%

Compounded Profit Growth
10 Years:	-3%
5 Years:	24%
3 Years:	35%
TTM:	-43%

Stock Price CAGR
10 Years:	4%
5 Years:	2%
3 Years:	-1%
1 Year:	-39%

Return on Equity
10 Years:	11%
5 Years:	0%
3 Years:	2%
Last Year:	3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	18	18	18	14	14	14	14	14	14	14	14	14
Reserves	849	936	1,045	2,666	2,606	2,517	2,543	2,604	2,421	2,424	2,437	2,703
	22	36	98	151	200	206	119	349	314	248	460	500
	264	283	359	359	323	407	436	351	444	589	659	520
Total Liabilities	1,153	1,274	1,521	3,190	3,142	3,145	3,112	3,319	3,193	3,275	3,569	3,737
	416	403	491	578	810	870	884	990	1,257	1,252	1,300	1,213
CWIP	123	237	250	238	92	330	568	494	147	123	31	100
Investments	41	14	14	901	926	550	392	264	2	1	0	0
	574	620	766	1,473	1,313	1,395	1,269	1,571	1,787	1,898	2,239	2,425
Total Assets	1,153	1,274	1,521	3,190	3,142	3,145	3,112	3,319	3,193	3,275	3,569	3,737

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	78	112	68	-112	-328	20	33	-260	-85	14	-7	4
	-52	-85	-132	1,648	-286	-36	-66	100	241	63	-242	192
	-51	-33	59	-881	-2	-62	-121	191	-81	-106	184	2
Net Cash Flow	-25	-7	-4	655	-616	-78	-154	32	75	-29	-65	198
Free Cash Flow	4	-28	-79	-271	-519	-360	-254	-386	-123	0	-142	163
CFO/OP	95%	87%	-237%	89%	424%	-49%	52%	-350%	160%	23%	4%	6%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	58	60	165	124	135	129	74	142	160	131	135	137
Inventory Days	171	184	397	278	278	374	518	527	414	365	418	349
Days Payable	114	131	297	230	182	236	202	161	193	174	170	128
Cash Conversion Cycle	116	113	265	172	231	267	390	508	382	322	382	358
Working Capital Days	88	90	174	133	165	154	163	207	207	173	159	169
ROCE %	9%	15%	9%	128%	-2%	-2%	2%	1%	-5%	-0%	6%	4%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Abbreviated New Drug Applications (ANDA) - Cumulative Filings
Number

xx	xx	xx		xx	xx	xx	xx	xx	xx	xx
x,xxx	x,xxx	x,xxx	x,xxx		x,xxx	x,xxx	x,xxx		x,xxx
		x	x		x	x		x	x	x
xx	xx	xx				xx		xx	xx	xx
			x		xx	x	x	x	x	x
xx	xx	xx	xx	xx						xx
					x	x	x	x	x	x
xx	xx	xx								xx
					x.xx				x.xx	xx.xx
xx	xx
							xx.xx	xx.xx	x.xx	x.xx

Please log in to see hidden values.

Total Employee Strength
Number

ANDA Filings during the Year
Number

Drug Master Files (DMF) - Cumulative US Filings
Number

Products Launched in US Generic Market during the Year
Number

ANDA Approvals - Cumulative
Number

ANDA Approvals during the Year
Number

CEP (European DMF) - Cumulative Filings
Number

Formulation Output Volume (Tablets/Capsules)
Billion Units

Chronic Therapy Contribution to Domestic Formulation Revenue
Percentage ・Standalone data

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	50.94%	70.21%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%
	1.62%	0.83%	0.84%	0.90%	0.89%	0.94%	1.05%	0.98%	0.98%	0.99%	0.99%	1.00%
	9.65%	10.00%	10.46%	11.26%	11.57%	11.65%	11.63%	11.32%	10.92%	10.74%	10.73%	10.63%
	37.80%	18.95%	18.47%	17.63%	17.32%	17.17%	17.11%	17.47%	17.88%	18.04%	18.05%	18.14%
No. of Shareholders	26,642	21,584	20,877	21,171	20,621	20,374	21,472	21,621	23,010	23,577	23,267	23,386

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	50.08%	50.67%	50.64%	50.74%	50.93%	50.93%	50.94%	70.22%	70.22%	70.22%
	4.04%	5.34%	2.13%	1.76%	1.50%	1.47%	1.70%	0.90%	0.98%	1.00%
	12.62%	5.93%	7.28%	9.46%	8.94%	9.59%	8.15%	11.26%	11.32%	10.63%
	33.26%	38.06%	39.95%	38.04%	38.62%	38.01%	39.21%	17.63%	17.47%	18.14%
No. of Shareholders	25,539	45,695	39,785	36,355	33,734	33,557	29,418	21,171	21,621	23,386

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Jun 2017

Transcript

AI Summary
PPT
Feb 2017
Transcript PPT
Nov 2016
Transcript PPT
Aug 2016
Transcript PPT
Jun 2016
Transcript PPT
Feb 2016
Transcript PPT